Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia

Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms

ASCO 2024: Lung cancer highlights

EHA 2024: Multiple myeloma roundup

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line

More effective treatment options required for patients with MM post lenalidomide exposure

PD-1–refractory advanced melanoma: how do we get to the finish line?

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma

Highlights in melanoma from ASCO 2024

Immunotherapy significantly increases the number of patients free from bowel cancer